Sanofi (NASDAQ:SNY) Releases Quarterly Earnings Results, Beats Estimates By $0.48 EPS

Sanofi (NASDAQ:SNY) issued its quarterly earnings results on Friday. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.56 by $0.48, Zacks reports. The company had revenue of $17.25 billion for the quarter, compared to analyst estimates of $14.29 billion. Sanofi had a return on equity of 14.19% and a net margin of 8.66%. The company’s quarterly revenue was up 16.2% compared to the same quarter last year. During the same period last year, the company earned $2.91 earnings per share.

Here are the key takeaways from Sanofi’s conference call:

• Q3 performance was strong: sales rose 14.3% to €14.4 billion, business operating income increased 19.7%, and business EPS grew 19.6%, supported by demand, favorable gross-to-net adjustments, product mix, and strict cost control.
• Sanofi upgraded its 2026 outlook to sales growth of 13%–15% and business EPS growth of 15%–17%. Management also expects business operating income and margin to increase annually through 2030, despite upcoming headwinds.
• Dupixent remained the central growth engine, generating €5.7 billion in Q3 with more than 1.5 million patients globally. Sanofi reaffirmed confidence in reaching at least €25 billion in annual sales by 2030 and expanded its Regeneron alliance with four next-generation immunology antibodies, including a potential long-acting follow-on product.
• Sanofi is concentrating resources on immunology, rare diseases, and vaccines while pursuing late-stage and commercial assets through disciplined BD and M&A. The company expects to provide more detail on its disease-area priorities, capital allocation, and Dupixent loss-of-exclusivity planning at a strategic update before year-end.
• R&D productivity remains a concern, with management acknowledging that Sanofi’s pipeline lags peers and discontinuing amlitelimab and itepekimab after benefit-risk reviews. The company also cautioned that 2027 sales will face roughly €1.3 billion of divestment-related reductions, a return to slightly negative pricing trends, and continued Dupixent profit-sharing and reimbursement headwinds.

Sanofi Trading Up 2.8%

NASDAQ:SNY traded up $1.21 during trading hours on Friday, hitting $44.34. The stock had a trading volume of 15,100,858 shares, compared to its average volume of 3,453,743. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.64 and a current ratio of 0.99. The business’s 50 day moving average is $42.21 and its 200-day moving average is $44.35. Sanofi has a one year low of $39.07 and a one year high of $52.68. The company has a market cap of $107.50 billion, a price-to-earnings ratio of 23.21, a P/E/G ratio of 1.33 and a beta of 0.33.

Key Sanofi News

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Sanofi reported third-quarter earnings of $2.04 per share, well above the $1.56 analyst consensus, while revenue of $17.25 billion exceeded estimates of $14.29 billion and rose 16.2% year over year. Sanofi earnings report
• Positive Sentiment: Dupixent remained the growth engine, generating approximately $6.36 billion in quarterly sales. Strong demand for the immunology treatment helped Sanofi raise its 2026 sales and business-earnings outlook. Sanofi Q3 earnings and outlook
• Positive Sentiment: The earnings beat and upgraded guidance are improving investor confidence in Sanofi’s near-term growth trajectory, with the stock reacting favorably despite broader weakness in technology shares. Sanofi profit and guidance update
• Neutral Sentiment: Chief Executive Officer Paul Hudson is considering acquisitions and other deals to replenish Sanofi’s pipeline ahead of Dupixent’s eventual patent expiration. Potential transactions could support future growth, but they also introduce execution and capital-allocation risks. Sanofi CEO discusses future deals
• Negative Sentiment: Despite the strong quarter, reported earnings declined from $2.91 per share in the prior-year period, underscoring the importance of sustained Dupixent growth and successful pipeline investments. Sanofi quarterly results

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on SNY. Morgan Stanley set a $49.00 price target on Sanofi in a report on Wednesday, July 8th. Wall Street Zen downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Wolfe Research began coverage on Sanofi in a research note on Friday, October 9th. They set a “peer perform” rating on the stock. DZ Bank reiterated a “buy” rating on shares of Sanofi in a research report on Friday, July 31st. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a report on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Sanofi has an average rating of “Hold” and a consensus target price of $49.50.

About Sanofi

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.